← Leaderboards
Christos Emmanouilides
University Of California Los Angeles
$830,967
Attributed
$830,967
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$830,967 · 5
By mechanism
M01$830,967 · 5
Top collaborators
No co-investigators on record.
Most similar at University Of California Los Angeles
Same institution · by research overlap
- William H. McBride$18,336,663
- Roberta K Oka$2,890,723
- Johannes Czernin$5,995,082
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchMonoclonal AntibodyHuman Therapy EvaluationDrug Screening /EvaluationAntineoplasticsNeoplasm /Cancer ImmunotherapyDrug Adverse EffectNonhodgkin'S LymphomaNeoplasm /Cancer Relapse /RecurrenceChronic Lymphocytic LeukemiaFludarabineNeoplasm /Cancer RadioimmunotherapyCombination Cancer TherapyB Cell LymphomaMedical ComplicationNeoplasm /Cancer Radionuclide TherapyQuality Of LifeAutologous TransplantationYttriumNeoplasm /Cancer Radiation TherapyClinical TrialsYtterbiumHematopoietic Stem Cells
Grant awards (8)
IDEC Y2 B8 RADIOIMMUNOTHERAPY COMPARED TO RITUXAN IMMUNOTHERAPY$207,266
M01 · FY2001 · RR
CAMPATH 1H IN PATIENTS W/ B CELL CHRONIC LYMPHOCYTIC LEUKEMIA$207,266
M01 · FY2001 · RR
IDEC Y2 B8 RADIOIMMUNOTHERAPY COMPARED TO RITUXAN IMMUNOTHERAPY$207,266
M01 · FY2001 · RR
PHASE III TRIAL OF RECOMBINANT HGF IN HEMATOLOGIC CANCER$0
M01 · FY2001 · RR
PHASE 2 TRIAL OF IDECOY2B8 IN B CELL NONHODGKIN'S LYHMPO$0
M01 · FY2001 · RR
TRIAL OF IDECY2B8 IN B CELL NONHODGKIN 'S LYMPHOMA$0
M01 · FY2001 · RR
CAMPATH 1H IN PATIENTS W/ B CELL CHRONIC LYMPHOCYTIC LEUKEMIA$207,266
M01 · FY2000 · RR
CAMPATH 1H IN PATIENTS W/ B CELL CHRONIC LYMPHOCYTIC LEUKEMIA$1,903
M01 · FY2000 · RR